Search results
Found 30691 matches for
A review of public comments on a proposed FDA regulatory framework, for modifications to artificial intelligence and machine learning-based software as a medical device, has found that 63% came from parties with financial ties to industry, and that the majority, 86% did not cite any scientific evidence.
Trials Expertise Session: Effective planning and management of trial sample collections
Tuesday, 04 November 2025, 10.30am to 11.30am
Trials Expertise Session: The role of a Trial Manager in a Trial Management Group (TMG) *online*
Thursday, 12 June 2025, 10am to 11am
Trials Expertise Session: Communication skills in Clinical Trials for Trial Managers *online*
Wednesday, 26 March 2025, 10am to 11am
Trials Expertise Session: Site Feasibility Questionnaires (SFQ) & Site selection *Hybrid*
Wednesday, 25 June 2025, 11am to 12pm
Meet the team
-
Gary Collins
Professor of Medical Statistics and Director of CSM
-
Andrew Carr
Nuffield Professor of Orthopaedics
Funded by
